Neoadjuvant and adjuvant therapy approaches to gastric cancer
C Fong, E Johnston, N Starling - Current treatment options in oncology, 2022 - Springer
Opinion statement Gastric cancer is an aggressive malignancy, requiring a multimodality
approach to achieve optimal curative rates even when the disease is amenable to surgical …
approach to achieve optimal curative rates even when the disease is amenable to surgical …
Gastric cancer: French intergroup clinical practice guidelines for diagnosis, treatments and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO)
A Zaanan, O Bouché, L Benhaim, B Buecher… - Digestive and Liver …, 2018 - Elsevier
Introduction This document is a summary of the French Intergroup guidelines regarding the
management of gastric cancer published in October 2016, available on the website of the …
management of gastric cancer published in October 2016, available on the website of the …
The Chinese Society of Clinical Oncology (CSCO): clinical guidelines for the diagnosis and treatment of gastric cancer, 2021
FH Wang, XT Zhang, YF Li, L Tang, XJ Qu… - Cancer …, 2021 - Wiley Online Library
There exist differences in the epidemiological characteristics, clinicopathological features,
tumor biological characteristics, treatment patterns, and drug selections between gastric …
tumor biological characteristics, treatment patterns, and drug selections between gastric …
Individual patient data meta-analysis of the value of microsatellite instability as a biomarker in gastric cancer
F Pietrantonio, R Miceli, A Raimondi… - Journal of Clinical …, 2019 - ascopubs.org
PURPOSE In the CLASSIC and MAGIC trials, microsatellite instability (MSI)–high status was
a favorable prognostic and potential negative predictive factor for neoadjuvant/adjuvant …
a favorable prognostic and potential negative predictive factor for neoadjuvant/adjuvant …
Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial
SH Noh, SR Park, HK Yang, HC Chung… - The lancet …, 2014 - thelancet.com
Background The CLASSIC trial was done to compare adjuvant capecitabine plus oxaliplatin
versus observation after D2 gastrectomy for patients with stage II or III gastric cancer. The …
versus observation after D2 gastrectomy for patients with stage II or III gastric cancer. The …
Emergency use of uridine triacetate for the prevention and treatment of life‐threatening 5‐fluorouracil and capecitabine toxicity
BACKGROUND Increased susceptibility to 5‐fluorouracil (5‐FU)/capecitabine can lead to
rapidly occurring toxicity caused by impaired clearance, dihydropyrimidine dehydrogenase …
rapidly occurring toxicity caused by impaired clearance, dihydropyrimidine dehydrogenase …
[HTML][HTML] Risk-adapted modulation through de-intensification of cancer treatments: an ESMO classification
D Trapani, MA Franzoi, HJ Burstein, LA Carey… - Annals of …, 2022 - Elsevier
Background The landscape of clinical trials testing risk-adapted modulations of cancer
treatments is complex. Multiple trial designs, endpoints, and thresholds for non-inferiority …
treatments is complex. Multiple trial designs, endpoints, and thresholds for non-inferiority …
Machine-learning model derived gene signature predictive of paclitaxel survival benefit in gastric cancer: results from the randomised phase III SAMIT trial
R Sundar, NB Kumarakulasinghe, YH Chan, K Yoshida… - Gut, 2022 - gut.bmj.com
Objective To date, there are no predictive biomarkers to guide selection of patients with
gastric cancer (GC) who benefit from paclitaxel. Stomach cancer Adjuvant Multi-Institutional …
gastric cancer (GC) who benefit from paclitaxel. Stomach cancer Adjuvant Multi-Institutional …
Can the tumor-agnostic evaluation of MSI/MMR status be the common denominator for the immunotherapy treatment of patients with several solid tumors?
D Fanale, LR Corsini, R Scalia, C Brando… - Critical Reviews in …, 2022 - Elsevier
Alterations in short-repetitive DNA sequences, known as microsatellite instability (MSI), can
reflect deficiencies in Mismatch Repair (MMR) system which represents a major player in …
reflect deficiencies in Mismatch Repair (MMR) system which represents a major player in …
[HTML][HTML] Early results of a randomized two-by-two factorial phase II trial comparing neoadjuvant chemotherapy with two and four courses of cisplatin/S-1 and docetaxel …
T Aoyama, K Nishikawa, K Fujitani, K Tanabe, S Ito… - Annals of …, 2017 - Elsevier
Background Neoadjuvant chemotherapy (NAC) is a promising method of improving the
survival of resectable gastric cancer. Cisplatin/S-1 (CS) and docetaxel/cisplatin/S-1 (DCS) …
survival of resectable gastric cancer. Cisplatin/S-1 (CS) and docetaxel/cisplatin/S-1 (DCS) …